Search results for " Central Nervous System"

showing 10 items of 47 documents

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)

2017

Leukemia : normal and malignant hemopoiesis 31(4), 846-852 (2017). doi:10.1038/leu.2016.334

MaleCancer Researchmedicine.medical_specialtyLymphomaPopulationMedizinProcarbazineGastroenterologyCentral Nervous System Neoplasms03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansImmunologic FactorseducationAgedNeoplasm StagingProportional Hazards ModelsAged 80 and overeducation.field_of_studyHematologybusiness.industryRemission InductionPrimary central nervous system lymphomaHematologyLomustinemedicine.diseaseSurgeryTumor BurdenMethotrexateTreatment OutcomeOncology030220 oncology & carcinogenesisCytarabineQuality of LifeMethotrexateRituximabOriginal ArticleFemalebusiness030215 immunologymedicine.drugLeukemia
researchProduct

Childhood central nervous system tumours – incidence and survival in Europe (1978–1997): Report from Automated Childhood Cancer Information System pr…

2006

Abstract This paper describes the incidence and survival of childhood central nervous system (CNS) tumours in Europe for the period 1978–1997. A total of 19,531 cases, aged 0–14 years, from the ACCIS database were analysed by five regions: the British Isles, East, North, South, and West. Overall age-standardised incidence rate (ASR) of CNS tumours in Europe (1988–1997) was 29.9 per million, with the highest rates in the North. Astrocytoma (ASR = 11.8), primitive neuroectodermal tumours (PNET) (ASR = 6.5) and ependymoma (ASR = 3.4) were the most frequent types. Incidence increased significantly during 1978–1997, on average by 1.7% per year. Diagnostic methods may partially explain incidence …

MaleEpendymomaCancer Researchmedicine.medical_specialtyAdolescentDatabases FactualChildhood cancerCentral nervous systemCentral Nervous System NeoplasmsEpidemiologymedicineHumansRegistriesChildcentral nervous system tumoursbusiness.industryIncidenceIncidence (epidemiology)Infant NewbornInfantChildhood cancers - survival - time trends; central nervous system tumoursAstrocytomaCancermedicine.diseaseSurvival AnalysisSurgeryEuropemedicine.anatomical_structureOncologyEl NiñoChild PreschoolFemalebusinessChildhood cancers - survival - time trendsDemographyEuropean Journal of Cancer
researchProduct

Identification of α-tubulin as an autoantigen recognized by sera from patients with neuropsychiatric systemic lupus erythematosus.

2011

In a previous study we found in 50% of patients with neuropsychiatric manifestations of systemic lupus erythematosus (NP-SLE) organ specific antibodies to 45-56 kD proteins in a 100,000 g supernatant (SN) from bovine brain mitochondria. Aim of the present study was to identify the corresponding target antigen. A 100,000 g SN from bovine brain mitochondria was applied to SDS-gel electrophoresis. A 50 kD band recognized by sera from patients with NP-SLE in the Western blot (WB) was excised from the gels and applied to mass spectrometry. The identified protein was expressed in Escherichia coli and retested against sera from eleven patients with NP-SLE (severe symptoms n=6, mild symptoms n=5), …

MalePathologyAutoantigenslaw.inventionBehavioral NeuroscienceEpilepsylawAntibody SpecificityTubulinLupus vasculitisCloning Molecularskin and connective tissue diseasesAged 80 and overbiologymedicine.diagnostic_testLupus Vasculitis Central Nervous SystemAntibodies MonoclonalMiddle AgedRecombinant ProteinsMitochondriaBlotRecombinant DNAElectrophoresis Polyacrylamide GelFemaleAntibodyAdultmedicine.medical_specialtyDNA ComplementaryMultiple SclerosisAdolescentImmunologyBlotting WesternNerve Tissue ProteinsYoung AdultWestern blotmedicineAnimalsHumansAgedBrain ChemistryEndocrine and Autonomic Systemsbusiness.industryMultiple sclerosisAutoantibodyCollagen Diseasesmedicine.diseaseSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationImmunologybiology.proteinCattlebusinessBrain, behavior, and immunity
researchProduct

Tuberculosis of the central nervous system in children: 32 years survey.

2005

Aim. In order to study the impact of clinical and diagnostic parameters on the clinical outcome of children with central nervous system tuberculosis (CNS-TB), we retrospectively reviewed all cases of CNS-TB diagnosed over a 32-year period at the Children's Hospital of Palermo, Italy. Methods. Data were collected with regard to the clinical, laboratory and demographic characteristics of patients, as well as the results of radiological investigations and data on clinical outcome. In relation to the date of introduction of new diagnostic methods (indirect as well direct) and to the change of treatment periods, the authors compared the clinical outcome of patients admitted prior and after 1984.…

MaleTime FactorsTuberculosis Central Nervous System diagnosis drug therapyTuberculin TestData CollectionAge FactorsAntitubercular AgentsInfantMycobacterium tuberculosisTuberculosis Central Nervous SystemTreatment OutcomeItalyChild PreschoolData Interpretation StatisticalHumansFemaleChildRetrospective StudiesMinerva pediatrica
researchProduct

Drug connectivity mapping and functional analysis reveal therapeutic small molecules that differentially modulate myelination

2022

Disruption or loss of oligodendrocytes (OLs) and myelin has devastating effects on CNS function and integrity, which occur in diverse neurological disorders, including Multiple Sclerosis (MS), Alzheimer’s disease and neuropsychiatric disorders. Hence, there is a need to develop new therapies that promote oligodendrocyte regeneration and myelin repair. A promising approach is drug repurposing, but most agents have potentially contrasting biological actions depending on the cellular context and their dose-dependent effects on intracellular pathways. Here, we have used a combined systems biology and neurobiological approach to identify compounds that exert positive and negative effects on olig…

MyelinMiceMyelin SheathNSC Neural stem cellSystems BiologyOPC Oligodendrocyte progenitor cellHigh-Throughput Nucleotide SequencingLINCS The Library of Integrated Network-based Cellular SignaturesCell DifferentiationGeneral MedicineCNS Central Nervous SystemOligodendrogliamedicine.anatomical_structureOligodendrogenesisNFOL Newly formed oligodendrocyteOL OligodendrocyteSignal TransductionSubventricular zoneOptic nerveIn silicoSystems biologyMorpholinesSVZ subventricular zoneContext (language use)RM1-950BiologyArticlemedicinePharmacogenomics The Library of Integrated Network-Based Cellular Signatures/LINCSAnimalsH-LY29 High concentration of LY294002Computer SimulationPI3K/AKT/mTOR pathwayL-LY29 Low concentration of LY294002PharmacologyPI3K/AktTCN TriciribineDose-Response Relationship DrugRegeneration (biology)Multiple sclerosismedicine.diseaseOligodendrocyteOligodendrocyteiNSCs iPSC-derived NSCsTAPs Transiently amplifying progenitorsMice Inbred C57BLMS Multiple SclerosisiPCS induced Pluripotent Stem CellChromonesPharmacogeneticsTherapeutics. PharmacologyMOL Myelinating oligodendrocyteNeuroscienceBiomedicine & Pharmacotherapy
researchProduct

Elimination of Established Risk-Factors in Primary Central Nervous System Lymphoma - Impact of High-Dose Chemotherapy Followed by Autologous Stem-Cel…

2011

Abstract Abstract 3089 Introduction: High-dose chemotherapy (HDT) and autologous stem-cell transplantation (ASCT) demonstrated high efficacy in the treatment of newly-diagnosed primary CNS lymphoma (PCNSL) in eligible patients (pts). Prognosis of PCNSL is associated with several clinical and histopathological risk factors (RF). Early complete response (CR) during chemotherapy (CHT) was recently reported to be an additional independent prognostic factor in pts undergoing polychemotherapy without HDT+ASCT. In this analysis, we examined the extent to which known RF determined survival in pts who were treated with HDT-ASCT. We additionally investigated the impact of HDT-ASCT specific factors (e…

Oncologymedicine.medical_specialtyChemotherapyPerformance statusbusiness.industryProportional hazards modelmedicine.medical_treatmentImmunologyPrimary central nervous system lymphomaCell BiologyHematologyThioTEPAmedicine.diseaseBiochemistryChemotherapy regimenSurgeryTransplantationInternal medicineMedicineStem cellbusinessmedicine.drugBlood
researchProduct

Superficial Siderosis of the Central Nervous System associated with Hemophilia A: A case report

2021

Abstract Superficial Siderosis of the Central Nervous System (SSCNS) is a condition secondary to the deposition of hemosiderin within the subpial layers of central nervous system leading to its progressive degeneration, clinically responsible for hearing impairment, cerebellar ataxia and pyramidal syndrome. Here we report the case of a 61-year-old man with medical history of congenital hemophilia A presenting with typical clinical features of SSCNS associated with extensive hypo-intensity on fast 2D gradient-echo-weighted sequences, along the spinal cord, posterior fossa's structures and cerebral cortex. Interestingly, although his disorder was revealed by a lumbar spinal stenosis, presurgi…

Pathologymedicine.medical_specialtyCentral nervous systemlcsh:SurgerySuperficial Siderosis of the Central Nervous System[INFO] Computer Science [cs]lcsh:RC346-429030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinemedicineMedical history[INFO]Computer Science [cs]lcsh:Neurology. Diseases of the nervous systemSubclinical infectionetiological diagnosisCerebellar ataxiabusiness.industryLumbar spinal stenosislcsh:RD1-811medicine.diseaseSpinal cordSuperficial siderosis3. Good healthmedicine.anatomical_structureCongenital Hemophilia AHemosiderinchronical bleedingSurgeryNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Image Analysis of Proliferating Cells in Tumors of the Human Nervous System

1994

Obtaining growth fractions from immunohistological preparations by the commonly used cell count calculation method is time consuming. For the first time, we investigated and compared the detection of proliferating cells in immunohistologically labeled tissue from tumors of the nervous system using the monoclonal antibody Ki-67 by a new computerized image analysis system and by cell count calculation. The two methods showed a high correlation (correlation index, 0.98) in 37 gliomas (2 pilocytic astrocytomas, 10 Grade II astrocytomas, 5 Grade III astrocytomas, 20 Grade IV astrocytomas and glioblastoma multiforme) and a heterogenous group of 10 additional tumors of the nervous system, includin…

PineoblastomaPathologymedicine.medical_specialtybiologybusiness.industryPrimary central nervous system lymphomaAstrocytomamedicine.diseaseKi-67GliomaImmunologymedicinebiology.proteinNeurofibromaSurgeryNeurology (clinical)OligodendrogliomabusinessAnaplastic astrocytomaNeurosurgery
researchProduct

Case of multifocal glioblastoma with four fusion transcripts of ALK, FGFR2, NTRK2, and NTRK3 genes stresses the need for tumor tissue multisampling f…

2021

Glioblastoma multiforme (GBM) is the most malignant brain tumor with patient mortality rate close to 100%, 5-yr survival rate of ∼5%, and a median survival of 14 mo. GBMs have notorious histomorphologic and molecular heterogeneities thus giving hope for development of future personalized therapies. We describe here a case of a 48-yr-old male patient with three-nodular GBM. To address the question of intratumoral molecular heterogeneity, a comparative analysis of gene expression was performed by using multiple samples collected from different tumor sites with the aid of intraoperative magnetic resonance imaging (MRI). Sixteen GBM biosamples from parietal, temporal, and temporo-polar localiza…

Research ReportMaleTemozolomideOncogene Proteins FusionBevacizumabBrain NeoplasmsglioblastomaRNAOncogenesGeneral MedicineMiddle AgedBiologyMagnetic Resonance ImagingTranscriptomeFusion transcriptGene expressionCancer researchmedicineHumansTranscriptomeGeneSurvival rateneoplasm of the central nervous systemmedicine.drugMolecular Case Studies
researchProduct

LIPID NANOPARTICLES AS CARRIERS FOR TARGETED RELEASE OF RILUZOLE INTO THE CENTRAL NERVOUS SYSTEM

2009

Settore CHIM/09 - Farmaceutico Tecnologico Applicativosolid lipid nanoparticles central nervous system drug delivery
researchProduct